3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: A phase II study

International Journal of Oncology

Volumn 12, Issue 6, 1998, Pages 1299-1306

  Cheung, Nai Kong V ^a   Kushner, Brian H ^a   Yeh, Samuel D J ^a   Larson, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

3F8 monoclonal antibody; Neuroblastoma; Phase II study

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIPODOPHYLLOTOXIN; GANGLIOSIDE GD2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG POTENCY; FEVER; HUMAN; HYPERTENSION; HYPOTENSION; INFANT; INTRAVENOUS DRUG ADMINISTRATION; NEUROBLASTOMA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY DISTRESS; URTICARIA;

EID: 0031814433     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.6.1299     Document Type: Article

References (35)

1. Brodeur GM and Castleberry RP: Neuroblastoma. In: Principles and Practice of Pediatric Oncology. 3rd edition. Pizzo PA and Poplack DG (eds.) J.B. Lippincott Company, Philadelphia, chapter 29, 1996.
2. Seeger RC, Villablanca JG, Matthay KK, Harris R, Moss TJ, Feig SA, Selch M, Ramsay N and Reynolds CP: Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. In: Prog Clin Biol Res: Advances in Neuroblastoma Research 3. Vol 366. Evans AE, D'Angio GJ, AG Knudson and Seeger RC (eds.) Wiley Liss, New York, pp527-534, 1991.
3. Cheung NK and Heller G: Chemotherapy dose intensity correlates strongly with response, median survival and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 9: 1050-1058, 1991.
4. Larson SM, Sgouros G and Cheung NK: Antibodies in cancer therapy: Radioisotope conjugates. In: Biologic Therapy of Cancer. 2nd edition. DeVita VT, Hellman S and Rosenberg SA (eds.) J.B. Lippincott Co., Philadelphia, pp534-552, 1995.
5. Levy R and Miller RA: Antibodies in cancer therapy: B-cell lymphomas. In: Biologic Therapy of Cancer. 1st edition. DeVita VT, Hellman S and Rosenberg SA (eds.) J.B. Lippincott Co., Philadelphia, pp512-522, 1991.
6. Miraldi FD, Nelson AD, Kraly C, Ellery S, Landmeier B, Coccia PF, Strandjord SE and Cheung NKV: Diagnostic imaging of human neuroblastoma with radiolabeled antibody. Radiology 161: 413-418, 1986.
7. Munn DH and Cheung NK: Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity (ADCC) against human melanoma. Cancer Res 47: 6600-6605, 1987.
8. Kushner BH and Cheung NK: GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73: 1936-1941, 1989.
9. Munn DH and Cheung NK: Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor. J Exp Med 172: 231-237, 1990.
10. Yeh SD, Larson SM, Burch L, Kushner BH, LaQuaglia M, Finn R and Cheung NKV: Radioimmunodetection of neuroblastoma with iodine-131-3F8: Correlation with biopsy, iodine-131-metaiodobenzylguanidine (MIBG) and standard diagnostic modalities. J Nucl Med 32: 769-776, 1991.
11. Cheung NKV, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML and Medof ME: Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest 81: 1122-1128, 1988.
12. Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF and Berger NA: Ganglioside GD2 specific monoclonal antibody 3F8 - a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5: 1430-1440, 1987.
13. Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF and Berger NA: Reassessment of patient response to monoclonal antibody 3F8. J Clin Oncol 10: 671-672, 1992.
14. Finklestein JZ, Klemperer MR, Evans A, Berstein I, Leikin S, McCreadie S, Grosfeld J, Hittie R, Weiner J, Sather H and Hammond D: Multiagent chemotherapy for children with metastatic neuroblastoma: a report from Childrens Cancer Study Group. Med Pediatr Oncol 6: 179-188, 1979.
15. Helson L, Castello MA, Arenson E, Steinherz L and Groshen S: An uncontrolled phase II study of continuous infusion vincristineadriamycin. In: Clinical Applications of Continuous Infusion Chemotherapy and Concomitant Radiation Therapy. Rosenthal CJ and Rotman M (eds.) Plenum Publishing Corp, New York, pp91-94, 1986.
16. Kushner BH and Helson L: Coordinated use of sequentially escalated cyclophosphamide and cell-cycle-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: experience with 100 patients. J Clin Oncol 5: 1746-1751, 1987.
17. Kushner BH, O'Reilly RJ, LaQuaglia M and Cheung NK: Dose intensive use of cyclophosphamide in ablation of neuroblastoma. Cancer 66: 1095-1100, 1990.
18. Kushner BH, LaQuaglia MP, Bonilla MA, Lindsley K, Rosenfield N, Yeh SDJ, Eddy J, Gerald WL, Heller G and Cheung NKV: Highly effective induction therapy for stage 4 neuroblastoma in children over one year of age. J Clin Oncol 12: 2607-2613, 1994.
19. Shafford EA, Rogers DW and Pritchard J: Advanced neuroblastoma: Improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM26. J Clin Oncol 2: 742-747, 1984.
20. Kushner BH, O'Reilly RJ, Mandell LR, Gulati SC, LaQuaglia M and Cheung NK: Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 9: 274-279, 1991.
21. Kushner BH, Gulati SC, Kwon J-H, O'Reilly RJ, Exelby PR and Cheung NKV: High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor-risk neuroblastoma. Cancer 68: 242-247, 1991.
22. D2 monoclonal antibody and human complement: a pilot study. In: Prog Clin Biol Res: Advances in Neuroblastoma Research. Vol 271. Evans AE, D'Angio GJ, Knudson AG and Seeger RC (eds.) Alan Liss, New York, pp 237-248, 1988.
23. Graham-Pole J, Casper J, Elfenbein G, Gee A, Gross S, Janssen W, Koch P, Marcus R, Pick T, Shuster J, Spruce W, Thomas P and Yeager A: High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9: 152-158, 1991.
24. Cheung NK, Cheung IY, Canete A, Yeh SJ, Kushner BH, Bonilla MA, Heller G and Larson SM: Antibody response to murine anti-GD2 monoclonal antibodies: Correlation with patient survival. Cancer Res 54: 2228-2233, 1994.
25. Cheung NK, Heller G, Kushner BH, Liu C and Cheung IY: Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive? J Clin Oncol 15: 2807-2817, 1997.
26. Brodeur G, Pritchard J, Berthold F, Carlen NLT, Castel V, Castleberry RP, DeBernardi B, Evans AE, Favrot M, Hedborg F, Kaneko M, Kemshead J, Lampert F, Lee REJ, Look T, Pearson ADJ, Philip T, Roald B, Sawada T, Seeger RC, Tsuchida Y and Voute PA: Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 11: 1466-1477, 1993.
27. Houghton AN, Chapman PB and Bajorin DF: Antibodies in cancer therapy: melanoma. In: Biologic Therapy of Cancer. 1st edition. DeVita VT, Hellman S, Rosenberg SA (eds.) J.B. Lippincott Co., Philadelphia, pp533-549, 1991.
28. Handgretinger R, Baader P, Dopfer R, Klingebiel T, Reuland P, Treuner J, Reisfeld RA and Niethammer D: A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 35: 199-204, 1992.
29. Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Pritsche HA, Benjamin RS, Legha SS, Ater JL, Jaffe N, Itoh K, Ross MI, Bucana CD, Thompson L, Cheung L and Rosenblum MG: Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12: 184-193, 1994.
30. Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M, Reuland P, Gillies SD, Reisfeld RA, Niethammer D: A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch 14.18 in patients with neuroblastoma. Eur Cancer 31: 261-267, 1995.
31. Albertini MR, Hank JA, Schiller JH, Khorsand M, Borchert AA, Gan J, Bechhofer R, Storer B, Reisfeld RA and Sondel PM: Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res 3: 1277-1288, 1997.
32. Saleh MN, Khazaeli MB, Wheeler RH, Allen L, Tilden AB, Reisfeld RA, Yu AL, Gillies SD and LoBuglio AF: Phase I trial of the chimeric anti-GD2 monoclonal antibody ch 14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 3: 19-24, 1992.
33. Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Jacek G, Anderson PM, Ettinger LJ, Cairo MS, Blazar BR, Krailo MD, Matthay KK, Reisfeld RA, Sondel PM: A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma. Cancer 80: 317-333, 1997.
34. D2 specific monoclonal antibodies. J Clin Oncol 4: 363-369, 1986.
35. Saleh MN, Khazaeli MB, Wheeler RH, Dropcho EJ, Liu T, Urist M, Miller DM, Larson S, Dixon P, Russell CM, LoBuglio AF: A phase I trial of the murine monoclonal anti-GD2 antibody 14.G2a in metastatic melanoma. Cancer Res 52: 4342-4347, 1992.